Abstract
As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Keywords: post-transcription modification, HDAC6, structure, cancer, selective inhibitor, histone deacetylation.
Current Medicinal Chemistry
Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors
Volume: 28 Issue: 21
Author(s): Yunpeng Zhao, Tao Liang, Xuben Hou*Hao Fang*
Affiliation:
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
Keywords: post-transcription modification, HDAC6, structure, cancer, selective inhibitor, histone deacetylation.
Abstract: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Zhao Yunpeng , Liang Tao, Hou Xuben*, Fang Hao *, Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653
DOI https://dx.doi.org/10.2174/0929867327666201111142653 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Intracellular Logistics of BST-2/Tetherin
Current HIV Research Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives
Current Protein & Peptide Science The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Filling the Pipeline - New Drugs for an Old Disease
Current Topics in Medicinal Chemistry Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience Cyclopeptides from Marine Organisms
Mini-Reviews in Organic Chemistry Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Antiangiogenic Therapy
Current Pharmaceutical Design Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs